CorMedix Inc. Common Stock (CRMD)

FairStock Score: 86/100 — HIGH CONVICTION

Key Financials

Strengths

• Generates $109 million in annual free cash flow (18.3% yield on market cap)
• High return on equity of 66.6% demonstrating efficient capital deployment
• Conservative balance sheet with debt-to-equity of just 0.37, providing financial flexibility
• Revenue growth of 312.1% demonstrates strong top-line momentum
• FairStock composite score of 86/100 places it in the top tier across value, quality, and momentum factors

Concerns

• Altman Z-Score of 1.2 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

CorMedix Inc. Common Stock is a micro-cap healthcare company valued at $593 million. The business generates $312 million in annual revenue with a 4.5% net margin and $109 million in free cash flow. From a quality standpoint, CorMedix shows solid Piotroski F-Score of 6/9 and distressed Altman Z-Score of 1.2 warrants caution. On valuation, the stock is deeply undervalued on a P/E basis at 3.6x, with offers a 51% margin of safety vs Graham Number of $15. Growth dynamics show revenue growing at 312.1% and profit growth of 4.1%. Our composite FairStock Score of 86/100 reflects strong fundamentals overall. This combination of reasonable valuation, solid returns, and conservative leverage makes it worth a closer look for value-oriented portfolios.

Bull Case

CorMedix's 312% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $109 million in annual free cash flow (18.3% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer